Pds biotechnology announces preclinical data for pds0203, a t-cell activating recombinant protein vaccine against covid-19

Pds biotech announces preclinical data for pds0203, a t-cell activating recombinant protein vaccine against covid-19.pds biotechnology-pds biotech generated robust preclinical data confirming pds0203 elicits induction of highly active, potent virus-specific cd8 killer.pds biotechnology corp - demonstrated induction of long-lasting virus-specific memory t-cells necessary for longer term protection.pds biotechnology corp - pds0203 demonstrated a 30-45 fold increase in covid-19 specific t-cells by day 14 when compared to vaccine without versamune.pds biotechnology-preclinical studies showed substantial increase in neutralizing antibody levels continuing more than 30 days after vaccination.
PDSB Ratings Summary
PDSB Quant Ranking